Skip to content
DataLookout
Menu

NCT07612280

Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 7 months later, primary endpoint(s) modified.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Jan 30, 2031 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 30 → 70 participants
    • Eligibility criteria shortened, about 1,393 words
    • Secondary endpoints: 8 to 3
    • Study description shortened, about 1,461 words
    • Site details revised at 2 of 7 sites
    • Study title shortened, about 3 words
  2. Minor Trial sites expanded: 1 → 7 locationsv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)
Timeframe: At the end of Cycle 1 (each cycle is 28 days)
Dose Expansion - Platelet count
Timeframe: Up to 2 years

Secondary (3)

Dose Escalation - Incidence of Treatment-Emergent Adverse Events (TEAEs)
Pharmacokinetic measures
Measures of clinical activity

Arms and interventions

Dose Escalation: Escalating oral dose of JBI-802Experimental

JBI-802 - CoREST inhibitor (Dual LSD1 and HDAC6 inhibitor)

Dose Expansion: Expansion arm at the RP2D of oral JBI-802Experimental

Drugs: JBI-802

Sites

7 sites in 1 country